Glia Diagnostics Pty Ltd

GLIA Diagnostics (GLIA) is dedicated to transforming the diagnosis and prognosis of traumatic brain injury (TBI), with a particular emphasis on mild TBI (mTBI)/concussion, to deliver better outcomes for patients worldwide. Our mission is to advance the understanding of brain injury through rigorous research, education, and the clinical validation of a novel biomarker suite. When integrated into a purpose-built point-of-care (POC) device, this platform will provide an objective and reliable tool for both diagnosis and prognosis. Our multidisciplinary team works closely with leading medical and scientific experts across the globe. By conducting robust clinical trials in diverse patient cohorts, we aim to validate our biomarker panel in parallel with complementary diagnostic modalities—establishing a comprehensive, evidence-based solution for concussion and broader TBI management. With proven expertise in biomedical science, diagnostics, translational research, and device development, GLIA is uniquely positioned to lead innovation in this critical field. We are building GLIA as a collaborative hub, bringing together synergistic partners across Australasia and internationally. We believe the future of TBI diagnostics will be defined by integrated biomarker panels and multimodal approaches, enabling precise, real-time decision-making in both clinical practice and frontline environments.